1. A 66-year-old man with severe COPD (chronic obstructive pulmonary disease) has been stable on sustained-release theophylline 600 mg daily for two years with a serum level of 15 mcg/mL. His psychiatrist initiates fluvoxamine for newly diagnosed obsessive-compulsive disorder. Three days later the patient calls reporting nausea, insomnia, and tremor. A theophylline level drawn the same day is 38 mcg/mL. Which of the following best explains the magnitude of this interaction and identifies the most appropriate immediate management step?
A) Fluvoxamine is a moderate CYP3A4 (cytochrome P450 3A4) inhibitor that has reduced theophylline clearance through its minor metabolic pathway; the interaction is predictable but modest, and the appropriate response is a 20% theophylline dose reduction followed by a repeat level in two weeks
B) Fluvoxamine has directly displaced theophylline from albumin binding sites, raising the free fraction of theophylline from approximately 60% to near 100% and producing toxicity; the total theophylline level of 38 mcg/mL overestimates true toxicity because much of the measured drug remains bound; free theophylline level measurement is required before any dose adjustment
C) Fluvoxamine is the most potent clinically used CYP1A2 (cytochrome P450 1A2) inhibitor, capable of increasing theophylline serum concentrations by up to three-fold through near-complete inhibition of theophylline's primary metabolic enzyme; theophylline should be withheld immediately, the patient should be evaluated for clinical toxicity requiring emergency care, and a markedly reduced theophylline dose with close level monitoring will be required if theophylline is continued at all
D) Fluvoxamine activates the pregnane X receptor (PXR), inducing CYP1A2 expression and paradoxically raising theophylline clearance; the rising theophylline level reflects a rebound phenomenon as the body compensates for reduced drug efficacy; the correct response is a temporary theophylline dose increase of 50% while the CYP induction stabilizes over two weeks
E) The interaction is pharmacodynamic rather than pharmacokinetic: fluvoxamine's serotonin reuptake inhibition raises CNS (central nervous system) serotonin levels, which cross-activate adenosine A1 receptors through serotonin-adenosine receptor heterodimerization, amplifying theophylline's pro-convulsant and pro-arrhythmic effects at a serum concentration that was previously safe; the theophylline dose is correct and fluvoxamine should be discontinued
ANSWER: C
Rationale:
Fluvoxamine holds a pharmacologically unique position in the CYP1A2 inhibitor landscape: it is the most potent clinically used CYP1A2 inhibitor, capable of reducing CYP1A2 activity to near-zero at therapeutic doses. While ciprofloxacin raises theophylline levels by 30–50% and cimetidine by 30–70%, fluvoxamine can increase theophylline concentrations by up to three-fold — a magnitude of interaction that is categorically more dangerous than other commonly encountered CYP1A2 inhibitors. In this patient, the serum theophylline level nearly tripled from 15 to 38 mcg/mL within three days of fluvoxamine initiation, consistent with near-complete CYP1A2 inhibition. At 38 mcg/mL, this patient is at significant risk for life-threatening cardiac arrhythmias and seizures. The immediate management priorities are: withhold theophylline, evaluate the patient clinically for evolving toxicity requiring emergency management, obtain cardiac monitoring given the arrhythmia risk at this concentration, and determine — after stabilization — whether theophylline therapy can continue at a substantially reduced dose with very close monitoring. If theophylline and fluvoxamine must be co-administered, dose reductions of 50–70% may be required with frequent level monitoring.
Option A: Option A is incorrect because fluvoxamine is not a moderate CYP3A4 inhibitor responsible for a modest interaction — it is the most potent CYP1A2 inhibitor in clinical use, and its interaction with theophylline is among the largest in magnitude of any drug-drug interaction affecting theophylline; a 20% dose reduction would be grossly inadequate and potentially fatal.
Option B: Option B is incorrect because fluvoxamine does not displace theophylline from albumin binding sites; theophylline is only approximately 40% protein-bound and protein displacement is not the mechanism of any significant theophylline drug interaction; the level of 38 mcg/mL reflects a true pharmacokinetic rise in total theophylline from CYP1A2 inhibition, not a measurement artifact from altered protein binding.
Option D: Option D is incorrect because fluvoxamine inhibits (not induces) CYP1A2; it does not activate the pregnane X receptor; a rising theophylline level in this context represents progressive accumulation from reduced clearance, not a rebound from increased clearance; increasing the theophylline dose in response would be catastrophically dangerous.
Option E: Option E is incorrect because fluvoxamine's mechanism of theophylline toxicity is pharmacokinetic — CYP1A2 inhibition raising theophylline plasma concentrations — not pharmacodynamic; serotonin-adenosine receptor heterodimerization is not an established mechanism of theophylline toxicity amplification; and the theophylline level of 38 mcg/mL confirms genuine drug accumulation requiring immediate dose management, not continuation.
2. A 74-year-old woman with COPD (chronic obstructive pulmonary disease) and known heart disease is brought to the emergency department by her daughter, who reports that she has been vomiting for 18 hours and is increasingly confused. Her ECG (electrocardiogram) shows multifocal atrial tachycardia at 144 beats per minute. Her serum potassium is 2.8 mEq/L. Her medication list includes sustained-release theophylline, ipratropium/albuterol inhaler, and aspirin. The daughter reports the patient started a new antibiotic four days ago for a respiratory infection but cannot recall the name. Which of the following is the most appropriate immediate next step and correctly identifies the clinical priority?
A) Obtain a stat serum theophylline level; the clinical triad of multifocal atrial tachycardia, hypokalemia, and vomiting in a theophylline-treated patient with a recent medication change is the classic presentation of theophylline toxicity, and the theophylline level will confirm the diagnosis and guide the urgency of intervention including the need for hemodialysis
B) Administer IV (intravenous) potassium chloride aggressively to normalize the serum potassium to greater than 4.0 mEq/L before any further diagnostic workup; the hypokalemia is the proximate cause of both the arrhythmia and the confusion and must be fully corrected before the primary underlying diagnosis can be established
C) Obtain blood cultures and initiate broad-spectrum antibiotics empirically; the presentation of tachycardia, confusion, and vomiting in a 74-year-old with recent antibiotic use and underlying lung disease most likely reflects sepsis from antibiotic-resistant respiratory pathogen, and the multifocal atrial tachycardia is a sepsis-driven arrhythmia rather than a drug toxicity effect
D) Administer IV amiodarone to achieve rate control and rhythm conversion of the multifocal atrial tachycardia; the arrhythmia is the most immediately life-threatening abnormality and antiarrhythmic therapy should be initiated before the underlying cause is identified, as delay in rhythm control increases the risk of hemodynamic compromise
E) Perform urgent echocardiography to evaluate for new wall motion abnormalities; the combination of tachycardia, hypokalemia, and confusion in a patient with known heart disease most likely represents an acute coronary syndrome with demand-induced hypokalemia from catecholamine surge, and echocardiography will identify any new systolic dysfunction requiring immediate catheterization
ANSWER: A
Rationale:
The clinical triad presented — multifocal atrial tachycardia, hypokalemia, and vomiting — in a patient on theophylline who recently had a medication change is the classic presentation of theophylline toxicity and warrants immediate diagnostic confirmation with a stat serum theophylline level. Each element of this triad has a defined mechanistic basis in theophylline toxicity: vomiting reflects GI toxicity from early-to-moderate theophylline excess, typically appearing at concentrations of 15–25 mcg/mL; hypokalemia reflects catecholamine-stimulated beta-2 adrenergic receptor activation driving potassium into skeletal muscle cells, reducing serum potassium; and multifocal atrial tachycardia is specifically associated with theophylline toxicity — particularly in patients with underlying lung disease — and results from adenosine A1 receptor antagonism at the SA (sinoatrial) node compounded by catecholamine excess. The recent antibiotic addition is clinically critical: the "antibiotic four days ago" very likely represents a CYP1A2 inhibitor (most probably a fluoroquinolone or macrolide) that reduced theophylline clearance. A stat theophylline level will confirm the diagnosis, establish severity, and determine whether the concentration threshold for hemodialysis has been met.
Option B: Option B is incorrect because while potassium replacement is necessary and will occur in parallel, administering potassium before establishing the diagnosis and concentration severity prioritizes one component of management over the diagnostic step that determines the full management plan including whether hemodialysis is urgently needed; the hypokalemia in theophylline toxicity is a transcellular shift driven by catecholamine excess and will not fully correct until theophylline concentrations are reduced.
Option C: Option C is incorrect because sepsis is a less parsimonious explanation for the specific triad of multifocal atrial tachycardia, hypokalemia, and vomiting in a theophylline-treated patient with a recent medication change; multifocal atrial tachycardia is characteristically associated with theophylline toxicity in patients with lung disease and is not typically a sepsis-driven arrhythmia pattern; empirical broad-spectrum antibiotics without establishing the correct diagnosis could delay life-saving intervention such as hemodialysis.
Option D: Option D is incorrect because amiodarone should not be administered before the underlying cause of multifocal atrial tachycardia is identified; in theophylline toxicity, the arrhythmia is driven by adenosine receptor antagonism and will not respond predictably to antiarrhythmic agents; moreover, amiodarone inhibits CYP1A2 and CYP2C9, which would further reduce theophylline clearance and worsen the underlying toxicity.
Option E: Option E is incorrect because acute coronary syndrome does not explain the complete clinical picture — specifically the vomiting and the characteristic pattern of multifocal atrial tachycardia — as well as the theophylline toxicity hypothesis does; demand-induced hypokalemia from catecholamine surge in ACS (acute coronary syndrome) is a secondary phenomenon and would not produce the magnitude of arrhythmia and vomiting seen here without a primary cardiac event that would typically present with chest pain or ST changes.
3. A 19-year-old collegiate cross-country runner with moderate persistent asthma is well controlled on fluticasone/salmeterol but continues to experience significant bronchospasm during the second half of long-distance races despite reliable pre-exercise albuterol use 15 minutes before competition. His FEV1 (forced expiratory volume in one second) at rest is 92% predicted. He denies symptoms between exercise sessions. Which of the following add-on agents is most pharmacologically appropriate for his breakthrough EIB (exercise-induced bronchoconstriction), and what is the mechanistic basis for expecting incremental benefit?
A) Add inhaled ipratropium bromide 10 minutes before exercise; anticholinergic blockade of muscarinic M3 receptors on airway smooth muscle will prevent the exercise-driven increase in parasympathetic tone that is the primary driver of EIB in competitive athletes, providing a mechanistically distinct bronchodilatory effect that complements albuterol's beta-2 adrenergic action
B) Add oral theophylline at a dose targeting serum concentrations of 8–12 mcg/mL; PDE (phosphodiesterase) 3 and 4 inhibition will raise baseline intracellular cAMP in airway smooth muscle and reduce the degree of bronchoconstriction triggered by exercise-induced airway cooling and hyperosmolarity, providing a sustained anti-EIB effect that outlasts albuterol's four-to-six-hour window
C) Add inhaled nedocromil sodium before each training session; mast cell stabilization through chloride channel blockade will prevent the exercise-triggered mast cell degranulation that releases cysteinyl leukotrienes and histamine, addressing the primary mediator source upstream of both the early and late phases of EIB without requiring daily systemic medication
D) Add montelukast 10 mg once daily; daily CysLT1 (cysteinyl leukotriene receptor 1) blockade will suppress the leukotriene-driven component of EIB that is not addressed by albuterol — cysteinyl leukotrienes released during exercise-triggered mast cell degranulation produce bronchoconstriction that is partially resistant to beta-2 agonist reversal — providing sustained protection throughout prolonged training sessions that outlasts SABA (short-acting beta-2 agonist) pre-treatment
E) Add high-dose inhaled budesonide as a second ICS on top of the existing fluticasone/salmeterol; the additive anti-inflammatory effect of dual ICS therapy will reduce airway mast cell density over six to eight weeks, decreasing the pool of cells available for exercise-triggered degranulation and producing a dose-dependent reduction in EIB severity
ANSWER: D
Rationale:
This athlete presents with a well-characterized clinical scenario: EIB that is refractory to pre-exercise SABA despite adequate baseline ICS/LABA control, occurring specifically during prolonged exercise sessions. The breakthrough pattern — occurring in the second half of long races — is consistent with a leukotriene-driven component that outlasts albuterol's protective window and is partially resistant to beta-2 agonist reversal. During exercise, airway cooling and hyperosmolarity trigger mast cell degranulation, releasing cysteinyl leukotrienes (LTC4, LTD4, LTE4) that act at CysLT1 receptors on airway smooth muscle. Cysteinyl leukotrienes are approximately 1000-fold more potent than histamine as bronchoconstrictors on a molar basis and their effect is prolonged and specifically less responsive to beta-2 agonist bronchodilation than histamine-mediated bronchoconstriction. Daily montelukast — through sustained CysLT1 receptor blockade throughout the 24-hour dosing interval — suppresses this leukotriene-driven component of EIB regardless of exercise duration, providing protection that does not wane as a single pre-exercise dose would. Montelukast is specifically FDA-approved for EIB prevention and is a guideline-supported add-on in patients with refractory EIB.
Option A: Option A is incorrect because EIB is not primarily driven by exercise-induced increases in parasympathetic tone to the airway; the principal mediator mechanisms are airway cooling and hyperosmolarity triggering mast cell degranulation with leukotriene and histamine release; anticholinergic agents have limited efficacy in EIB and are not guideline-supported add-on therapy for this indication.
Option B: Option B is incorrect because while theophylline has bronchodilatory properties through PDE inhibition, it is not recommended as an add-on controller agent for EIB in a young competitive athlete with otherwise well-controlled asthma; its narrow therapeutic index, complex drug interaction profile, and need for serum level monitoring make it an inappropriate choice when a more targeted, safer, and evidence-supported option (montelukast) is available.
Option C: Option C is incorrect because inhaled nedocromil — a mast cell stabilizer — has largely fallen out of use and is not a guideline-supported add-on for refractory EIB in adults or competitive athletes; while it can prevent allergen-triggered bronchoconstriction when used prophylactically, it is inferior to both ICS and LTRAs for asthma management and is not the appropriate selection for this clinical scenario.
Option E: Option E is incorrect because adding a second ICS on top of an existing ICS/LABA combination is not a guideline-endorsed step for EIB management; dual ICS therapy does not provide incremental anti-inflammatory benefit over single-agent ICS at appropriate doses; escalating ICS therapy addresses eosinophilic airway inflammation but does not specifically target the exercise-triggered leukotriene pathway that is responsible for this patient's breakthrough EIB.
4. A 38-year-old woman with severe persistent asthma has been on zafirlukast 20 mg twice daily for eight months. Her pulmonologist recently tapered her oral prednisone from 20 mg daily to 5 mg daily over the preceding six weeks due to improved asthma control. She now presents with worsening dyspnea, new peripheral eosinophilia (eosinophil count 3,800 cells/mcL), a purpuric rash on her lower extremities, and bilateral foot drop. Her chest radiograph shows bilateral pulmonary infiltrates. Which of the following most accurately identifies this clinical syndrome and determines the correct management approach?
A) This presentation represents zafirlukast-induced CYP2C9 inhibition causing accumulation of an unmeasured endogenous substrate that produces systemic eosinophilia and vasculitis; zafirlukast should be continued and the eosinophilia treated with hydroxyurea while the prednisone taper is completed as planned
B) This presentation is consistent with eosinophilic granulomatosis with polyangiitis (EGPA, formerly Churg-Strauss syndrome), likely unmasked by the corticosteroid taper rather than caused by zafirlukast directly; the association with LTRA (leukotriene receptor antagonist) therapy during steroid tapering likely reflects unmasking of pre-existing subclinical EGPA as systemic corticosteroid suppression is withdrawn; zafirlukast should be discontinued, and systemic corticosteroids should be reinstituted at doses sufficient to control the vasculitic process, with prompt rheumatology and pulmonology evaluation
C) This presentation represents a predictable pharmacodynamic effect of zafirlukast at eight months of therapy — late-onset CysLT1 (cysteinyl leukotriene receptor 1) hypersensitization producing paradoxical leukotriene pathway upregulation — and is best managed by switching to zileuton, which acts upstream at 5-LOX (5-lipoxygenase) and will suppress the constitutive leukotriene overproduction driving the eosinophilic vasculitis
D) The peripheral neuropathy and purpuric rash confirm a diagnosis of warfarin-induced skin necrosis precipitated by zafirlukast's CYP2C9 inhibitory effect on warfarin metabolism; the treatment is immediate cessation of zafirlukast, fresh frozen plasma to restore clotting factors, and transition to a non-CYP2C9-dependent anticoagulant
E) This is a Type IV hypersensitivity reaction to zafirlukast mediated by sensitized CD8 (cluster of differentiation 8) T lymphocytes; it is dose-dependent and resolves completely within two weeks of drug discontinuation without corticosteroid therapy; the prednisone taper should be accelerated, not reversed, to avoid masking any remaining hypersensitivity response
ANSWER: B
Rationale:
This clinical presentation — worsening asthma, systemic eosinophilia, purpuric vasculitic rash, peripheral neuropathy (foot drop), and pulmonary infiltrates — occurring during a prednisone taper in a patient on an LTRA is the classic description of eosinophilic granulomatosis with polyangiitis (EGPA), formerly known as Churg-Strauss syndrome. The relationship between LTRA therapy and EGPA is an important and nuanced one: available evidence and post-marketing case analysis suggest that zafirlukast (and to a lesser extent other LTRAs) does not directly cause EGPA but rather that systemic corticosteroid tapering unmasks pre-existing subclinical EGPA that had been suppressed by the corticosteroids. The LTRA therapy is often the agent that allowed the prednisone taper to proceed — thus the apparent temporal association between LTRA use and EGPA emergence during taper. Regardless of the mechanism, the clinical management requires: discontinuing zafirlukast (since its contribution to the clinical picture cannot be fully excluded), promptly reinstituting systemic corticosteroids at doses adequate to control the vasculitic and eosinophilic process (high-dose prednisone, typically 1 mg/kg/day), and urgent subspecialty evaluation — rheumatology for EGPA management and neurology for the peripheral neuropathy. The bilateral foot drop indicates mononeuritis multiplex, a serious manifestation of vasculitic neuropathy that requires aggressive immunosuppressive treatment to prevent irreversible neurological deficit.
Option A: Option A is incorrect because this presentation is not a pharmacokinetic consequence of CYP2C9 inhibition by zafirlukast; the syndrome described — systemic eosinophilia, vasculitic rash, neuropathy, and pulmonary infiltrates — is EGPA, a systemic necrotizing vasculitis requiring immunosuppressive treatment, not a drug accumulation phenomenon manageable with hydroxyurea; continuing zafirlukast and completing the prednisone taper would allow a dangerous vasculitic process to progress unchecked.
Option C: Option C is incorrect because zafirlukast does not cause late-onset CysLT1 hypersensitization or paradoxical leukotriene pathway upregulation as a recognized mechanism; switching to zileuton would not address the systemic vasculitic process, which requires corticosteroid-based immunosuppression; this option misidentifies the pathophysiology entirely.
Option D: Option D is incorrect because warfarin-induced skin necrosis requires the patient to be on warfarin, which is not mentioned in this case; the purpuric rash in EGPA is a vasculitic palpable purpura, not a coagulation necrosis pattern; peripheral neuropathy and pulmonary infiltrates are not features of warfarin skin necrosis.
Option E: Option E is incorrect because EGPA is not a Type IV CD8 T-cell hypersensitivity reaction to zafirlukast; it is a systemic eosinophilic necrotizing vasculitis driven by eosinophilic granulomatous inflammation; it does not resolve within two weeks of drug discontinuation without corticosteroids — it requires aggressive systemic immunosuppression; accelerating the prednisone taper would be the opposite of the correct management and would produce rapid clinical deterioration.
5. A 44-year-old woman with AERD (aspirin-exacerbated respiratory disease), moderate asthma, and severe nasal polyposis has undergone four functional endoscopic sinus surgeries (FESS) over eight years for recurrent polyp regrowth. She has no cardiovascular disease, no peptic ulcer history, and her asthma is moderately well controlled on ICS/LABA (inhaled corticosteroids/long-acting beta-2 agonist) plus montelukast. She asks her allergist whether aspirin desensitization would help prevent further polyp recurrence. Which of the following most accurately assesses her candidacy for aspirin desensitization and explains the pharmacological mechanism through which it may reduce polyp recurrence?
A) She is not a candidate for aspirin desensitization because she has no cardiovascular indication requiring aspirin; the procedure is reserved exclusively for AERD patients who need ongoing aspirin therapy for a medical indication such as coronary artery disease or stroke prevention, and performing desensitization purely for disease modification in the absence of a cardiovascular indication is outside the approved scope of the procedure
B) She is a candidate, but aspirin desensitization is expected to benefit only her lower airway asthma symptoms and will have no effect on nasal polyposis, because nasal polyp formation is driven by IL-5 (interleukin-5)-mediated eosinophil recruitment and TGF-beta (transforming growth factor-beta) fibrosis rather than by the leukotriene pathway; targeted biologic therapy with mepolizumab would be more appropriate for her polyp burden
C) She is an ideal candidate; however, she must discontinue montelukast at least four weeks before the desensitization procedure because montelukast's CysLT1 (cysteinyl leukotriene receptor 1) receptor blockade will blunt the early-phase leukotriene surge required to trigger the receptor downregulation that is the mechanistic basis for desensitization; proceeding without montelukast washout will result in failed desensitization
D) She is not a candidate because her four prior sinus surgeries represent a formal contraindication to aspirin desensitization; post-surgical disruption of the nasal mucosal architecture alters the mast cell and eosinophil distribution in the sinonasal mucosa, producing an unpredictable aspirin challenge response that makes graduated dose escalation unsafe in patients with prior FESS
E) She is a strong candidate for aspirin desensitization as a disease-modifying intervention; successful desensitization and maintenance aspirin therapy has been associated in observational studies with significant reductions in nasal polyp recurrence rates, sinus surgery frequency, and oral corticosteroid requirements; the proposed mechanism involves CysLT1 receptor downregulation and EP2 (prostaglandin E2 receptor subtype 2) upregulation restoring the PGE2-mediated anti-inflammatory restraint on mast cell and eosinophil 5-LOX (5-lipoxygenase) activity that is constitutively deficient in AERD
ANSWER: E
Rationale:
This patient is an ideal candidate for aspirin desensitization as a disease-modifying intervention. While aspirin desensitization is particularly compelling when a concurrent cardiovascular indication exists, disease modification in refractory sinonasal polyposis is a well-recognized and guideline-supported indication in its own right — especially in patients with recurrent polyp regrowth despite multiple surgeries, as in this case with four prior FESS procedures. Observational studies of aspirin desensitization in AERD have consistently shown significant reductions in nasal polyp recurrence rates, sinus surgery frequency, and oral corticosteroid requirements in patients who successfully complete desensitization and maintain continuous aspirin therapy. The proposed pharmacological mechanism is coherent: AERD is characterized by constitutively deficient PGE2 production and reduced EP2-mediated inhibitory tone on mast cell and eosinophil 5-LOX activity in the sinonasal and bronchial mucosa. Aspirin desensitization appears to produce progressive CysLT1 receptor downregulation on mast cells and eosinophils, reducing their responsiveness to the constitutively elevated cysteinyl leukotrienes in AERD tissue; simultaneously, continuous aspirin maintenance may upregulate EP2 receptor expression, partially restoring the PGE2-mediated anti-inflammatory restraint that is pathologically deficient in AERD. The cumulative pharmacological effect reduces the leukotriene-driven eosinophilic inflammation driving polyp growth and regrowth.
Option A: Option A is incorrect because aspirin desensitization is a recognized and guideline-supported disease-modifying intervention for AERD patients with severe sinonasal disease — not an intervention reserved exclusively for those with cardiovascular indications; severe refractory polyposis with multiple surgeries is a compelling disease-modification indication independent of any cardiovascular need.
Option B: Option B is incorrect because while IL-5-mediated eosinophilic inflammation and TGF-beta-driven fibrosis contribute to nasal polyp pathophysiology, the leukotriene pathway — specifically the constitutively elevated cysteinyl leukotriene production — is a central and pharmacologically targetable driver of eosinophilic sinonasal inflammation in AERD; aspirin desensitization has demonstrated clinically meaningful reductions in polyp recurrence in observational data, and the claim that it will have no effect on polyposis is not supported by the available evidence.
Option C: Option C is incorrect because montelukast does not need to be discontinued before aspirin desensitization; CysLT1 receptor blockade by montelukast does not prevent the receptor downregulation that occurs during desensitization; the mechanism of desensitization does not require an unblocked early-phase leukotriene surge at CysLT1 receptors to proceed successfully; montelukast continuation during and after desensitization is clinically appropriate and commonly practiced.
Option D: Option D is incorrect because prior sinus surgery is not a formal contraindication to aspirin desensitization; FESS does not alter the mast cell and eosinophil distribution in a manner that makes aspirin challenge unpredictable or unsafe; patients with multiple prior sinus surgeries are among those most likely to benefit from aspirin desensitization as a disease-modifying intervention to reduce further polyp regrowth.
6. A 7-year-old boy with mild persistent asthma is brought to his pediatrician by his parents, who strongly refuse inhaled corticosteroid (ICS) therapy after reading that "steroids stunt growth and suppress the immune system." They request an alternative controller medication. The child has no psychiatric history and no prior medication trials. Which of the following represents the most appropriate clinical response, and what is the pharmacological reasoning for the preferred agent?
A) Prescribe cromolyn sodium nebulizer solution four times daily as the preferred non-steroid alternative, since cromolyn has a superior safety profile to any other controller option, equivalent anti-inflammatory efficacy to low-dose ICS in children, and no systemic adverse effects; the four-times-daily regimen is the most practical option for school-aged children and provides all-day protection with minimal adherence challenge
B) Prescribe zafirlukast 10 mg twice daily as the preferred LTRA (leukotriene receptor antagonist) in this age group because it carries no neuropsychiatric boxed warning, unlike montelukast, and its CYP2C9 (cytochrome P450 2C9) metabolic profile has been well studied in pediatric populations; its twice-daily dosing also improves compliance by distributing the dose across mealtimes
C) Engage the family in shared decision-making about the genuine, well-established risks of ICS at low doses (modest and monitored growth effect, minimal HPA [hypothalamic-pituitary-adrenal] axis suppression) versus the unaddressed risk of poorly controlled asthma, while simultaneously discussing montelukast as the most practical non-ICS alternative given its once-daily oral dosing and absence of inhalation technique requirements; counsel the family specifically on the FDA neuropsychiatric boxed warning and document the informed discussion before prescribing
D) Prescribe low-dose ICS over the family's objection because physician judgment supersedes parental refusal in cases where the standard of care for a pediatric patient is well established; parental refusal of guideline-recommended first-line therapy constitutes medical neglect, and the physician is obligated to initiate ICS therapy regardless of family preference
E) Prescribe montelukast 5 mg daily without specifically discussing the neuropsychiatric boxed warning because disclosure of rare adverse events in a 7-year-old without psychiatric history constitutes unnecessary alarm that will reduce medication adherence; the benefit of improved asthma control outweighs the theoretical risk, and the warning applies primarily to adults with established psychiatric histories rather than healthy young children
ANSWER: C
Rationale:
This scenario requires integrating pharmacological knowledge with the clinical reality of shared decision-making when a family declines guideline-recommended therapy. The most appropriate response is not to override the family or to prescribe without adequate counseling, but to engage the family transparently. The physician should first address the family's concerns about ICS with accurate, calibrated information: low-dose ICS in children produces a modest, temporary effect on growth velocity (approximately 0.5 cm in the first year with little cumulative effect beyond that) and minimal HPA axis suppression at guideline-recommended doses — risks that are substantially less than those of poorly controlled asthma, including exacerbations, hospitalizations, and long-term airway remodeling. If the family continues to decline ICS after informed discussion, montelukast (5 mg chewable tablet once daily in children aged 6–14) is the most clinically practical non-ICS alternative: once-daily oral dosing addresses the adherence challenge of inhaler technique in young children, and its established pediatric efficacy in mild persistent asthma is supported by guideline inclusion as a Step 2 alternative. However, prescribing montelukast in any patient requires specific counseling on the FDA March 2020 neuropsychiatric boxed warning — the family must be told about the risk of agitation, behavioral changes, depression, and suicidal ideation, and instructed to discontinue and contact the prescriber immediately if such symptoms develop. This counseling must be documented.
Option A: Option A is incorrect because cromolyn is not equivalent in efficacy to low-dose ICS in children — multiple controlled trials have demonstrated ICS superiority in reducing exacerbations and airway hyperresponsiveness; and the four-times-daily dosing of cromolyn creates substantial adherence challenges for school-aged children, making it a less practical option; it is not the most appropriate choice.
Option B: Option B is incorrect because zafirlukast is not FDA-approved for children under 7 years and requires twice-daily empty-stomach dosing that creates practical challenges; the claim that it carries no neuropsychiatric warning concerns is accurate, but the claim that it has been "well studied in pediatric populations" is overstated relative to montelukast's far more extensive pediatric evidence base; montelukast is the preferred LTRA in the pediatric setting at this age.
Option D: Option D is incorrect because parental refusal of ICS in a child with mild persistent asthma does not constitute medical neglect, and a physician cannot override informed parental decision-making for a non-emergency situation without legal authority; the appropriate response is thorough counseling and offering evidence-based alternatives within shared decision-making, not unilateral prescription over parental objection.
Option E: Option E is incorrect because the FDA neuropsychiatric boxed warning for montelukast applies to all age groups, including children as young as 2 years — it is not restricted to adults with established psychiatric histories; withholding disclosure of a boxed warning to avoid "unnecessary alarm" is both ethically inappropriate and legally indefensible; proper counseling and documentation are mandatory before prescribing montelukast.
7. A 70-year-old man with COPD (chronic obstructive pulmonary disease) maintained on sustained-release theophylline (serum level 13 mcg/mL) is admitted for community-acquired pneumonia. The admitting team considers antibiotic options and discusses the theophylline interaction risk. The attending notes that levofloxacin is being considered because it has less CYP1A2 (cytochrome P450 1A2) inhibitory potential than ciprofloxacin. Which of the following most accurately characterizes the levofloxacin-theophylline interaction and the appropriate clinical management?
A) Levofloxacin produces less CYP1A2 inhibition than ciprofloxacin and consequently raises theophylline levels to a lesser degree — typically by 10–20% rather than the 30–50% seen with ciprofloxacin; this does not eliminate the interaction risk entirely, particularly in a patient already at 13 mcg/mL, and a theophylline serum level should be checked within two to three days of starting levofloxacin with clinical monitoring for early toxicity symptoms
B) Levofloxacin has no CYP1A2 inhibitory activity whatsoever and is completely safe to co-administer with theophylline at any serum concentration without dose adjustment or additional level monitoring; it can be used as the preferred fluoroquinolone in all theophylline-treated patients without restriction
C) All fluoroquinolone antibiotics inhibit CYP1A2 to an identical degree because the CYP-inhibitory property is a class effect of the fluoroquinolone pharmacophore; choosing levofloxacin over ciprofloxacin provides no safety advantage in theophylline-treated patients, and the theophylline dose should be empirically reduced by 40% before initiating any fluoroquinolone
D) Levofloxacin inhibits CYP3A4 (cytochrome P450 3A4) rather than CYP1A2, making its theophylline interaction mechanistically distinct from ciprofloxacin's; because CYP3A4 accounts for only a minor fraction of theophylline clearance, levofloxacin's net effect on theophylline concentrations is less clinically significant than ciprofloxacin's, but a 20% empiric theophylline dose reduction is still required before starting levofloxacin
E) The theophylline-fluoroquinolone interaction is entirely pharmacodynamic rather than pharmacokinetic: all fluoroquinolones, including levofloxacin, antagonize GABA-A (gamma-aminobutyric acid type A) inhibitory neurotransmission in the CNS (central nervous system) through the same mechanism as theophylline's adenosine A1 antagonism, producing additive pro-convulsant effects; this pharmacodynamic synergy is the primary concern rather than any change in theophylline serum concentrations
ANSWER: A
Rationale:
The fluoroquinolone class shows clinically meaningful variability in CYP1A2 inhibitory potency. Ciprofloxacin is the most potent CYP1A2 inhibitor among fluoroquinolones in common clinical use, reducing theophylline clearance by approximately 30–50% and producing corresponding rises in serum theophylline concentrations that can reach toxic levels within days. Levofloxacin has substantially less CYP1A2 inhibitory activity than ciprofloxacin, producing theophylline level increases typically in the range of 10–20% — clinically meaningful but considerably less dangerous than the ciprofloxacin interaction. Moxifloxacin has even less CYP1A2 interaction with theophylline than levofloxacin. However, "less CYP1A2 inhibition" does not mean "no CYP1A2 inhibition": in a patient already at 13 mcg/mL — approaching the upper boundary of the 10–20 mcg/mL therapeutic window — even a 10–20% rise could produce a level of 14.3–15.6 mcg/mL under optimal circumstances, but with the pharmacokinetic variability of an acutely ill patient with pneumonia, combined effects from the infection itself (interferon-mediated CYP suppression), and potential CHF or hepatic congestion could compound the level rise substantially. The clinically appropriate response is to proceed with levofloxacin (acknowledging its relative advantage over ciprofloxacin) while checking a theophylline serum level within two to three days and monitoring clinically for GI symptoms, palpitations, and tremor — the early warning signs of theophylline toxicity.
Option B: Option B is incorrect because levofloxacin is not completely devoid of CYP1A2 inhibitory activity; while its interaction magnitude with theophylline is smaller than ciprofloxacin's, it is not zero, and characterizing it as requiring "no dose adjustment or additional level monitoring" is clinically inaccurate and potentially dangerous — particularly in acutely ill patients with concurrent physiological stressors on theophylline clearance.
Option C: Option C is incorrect because CYP1A2 inhibitory potency is not a uniform class effect of the fluoroquinolone pharmacophore; there is clinically significant variability within the class — ciprofloxacin >> levofloxacin > moxifloxacin in terms of CYP1A2 inhibition and theophylline interaction magnitude; choosing levofloxacin over ciprofloxacin does provide a meaningful safety advantage.
Option D: Option D is incorrect because levofloxacin's theophylline interaction is mediated primarily through CYP1A2 inhibition (not CYP3A4); while the magnitude is less than ciprofloxacin's, the enzyme target is the same primary pathway; a 20% empiric dose reduction before starting levofloxacin is not the standard clinical approach — monitoring with level checking after initiation is preferred over empiric pre-emptive dose reduction.
Option E: Option E is incorrect because while fluoroquinolones can lower the seizure threshold through GABA-A receptor effects — a recognized class concern — the primary clinical pharmacokinetic interaction between fluoroquinolones and theophylline is CYP1A2-mediated pharmacokinetic elevation of theophylline levels; the pharmacodynamic GABA-A antagonism is a secondary consideration and is not characterized as "the primary concern" over the well-established pharmacokinetic interaction.
8. A 31-year-old woman at 28 weeks of gestation is diagnosed with moderate persistent asthma for the first time, presenting with daily symptoms and two nocturnal awakenings per week. Her FEV1 (forced expiratory volume in one second) is 74% predicted. She is not on any controller medication. She asks whether she can take montelukast because she prefers an oral agent and has read that inhaled steroids "might affect the baby." Which of the following most accurately addresses her clinical question and identifies the pharmacologically and clinically preferred controller approach?
A) Montelukast is the preferred first-line controller in pregnancy because oral medications have more predictable pharmacokinetics than inhaled agents, whose lung deposition varies with gestational breathing pattern changes; the FDA neuropsychiatric boxed warning does not apply during pregnancy because fetal CysLT1 (cysteinyl leukotriene receptor 1) receptor development is incomplete before 34 weeks and CNS (central nervous system) exposure is therefore negligible
B) Neither montelukast nor inhaled corticosteroids (ICS) should be initiated in the third trimester because any controller medication initiated after 24 weeks carries teratogenic risk through placental transfer; the patient should be managed with as-needed SABA (short-acting beta-2 agonist) albuterol alone until delivery and then started on controller therapy postpartum
C) Montelukast is an acceptable alternative to ICS in pregnancy and is preferred in the third trimester specifically because ICS systemic absorption increases as gestational lung volume decreases and the resultant higher systemic glucocorticoid exposure poses an unacceptable fetal adrenal suppression risk that is avoided by montelukast's non-steroidal mechanism
D) Low-dose inhaled budesonide is the preferred first-line controller agent for moderate persistent asthma in pregnancy; it has the most extensive human pregnancy safety data among ICS agents, is classified as FDA Pregnancy Category B (former classification), and is recommended by NAEPP (National Asthma Education and Prevention Program) guidelines as the ICS of choice in pregnancy; poorly controlled asthma carries substantially greater fetal risk — including preeclampsia, preterm birth, and intrauterine growth restriction — than appropriately dosed ICS; montelukast has more limited human pregnancy data and is not preferred as first-line therapy in this setting
E) The preferred approach is to initiate montelukast now and add low-dose ICS only if montelukast fails to achieve asthma control within four weeks; this stepwise approach minimizes fetal ICS exposure during the critical third-trimester period of fetal lung maturation and aligns with the GINA (Global Initiative for Asthma) recommendation that non-steroidal controllers should always be trialed before ICS in pregnant patients
ANSWER: D
Rationale:
The preferred first-line controller agent for moderate persistent asthma in pregnancy is inhaled budesonide at an appropriate low-to-medium dose, not montelukast. This recommendation rests on several pharmacological and clinical foundations. Budesonide has the most extensive and reassuring human pregnancy safety data of any inhaled corticosteroid, accumulated over decades of use in pregnant women with asthma in Nordic countries and elsewhere; it carries former FDA Pregnancy Category B status (the only ICS to achieve this designation) and is specifically recommended by the NAEPP (National Asthma Education and Prevention Program) as the ICS of choice when initiating or maintaining asthma controller therapy during pregnancy. Inhaled corticosteroids at low-to-moderate doses produce negligible systemic absorption and do not produce clinically meaningful fetal HPA (hypothalamic-pituitary-adrenal) axis suppression at guideline-recommended doses — the patient's concern about "affecting the baby" reflects a common misconception about the dose-systemic absorption relationship of low-dose inhaled therapy. Crucially, the fetal and maternal risks of poorly controlled asthma in the third trimester are substantial and well documented: preeclampsia, preterm birth, low birth weight, intrauterine growth restriction, and perinatal mortality are all increased in women with uncontrolled asthma during pregnancy. These fetal risks far exceed the theoretical systemic risks of appropriately dosed ICS. Montelukast has more limited human pregnancy safety data, is not preferred as first-line therapy in pregnancy, and its neuropsychiatric boxed warning applies regardless of gestational status.
Option A: Option A is incorrect because montelukast is not the preferred first-line controller in pregnancy; the claim that the neuropsychiatric boxed warning does not apply during pregnancy due to incomplete fetal CysLT1 receptor development is not an established FDA position or pharmacological basis for excluding the warning; the preferred agent is inhaled budesonide based on established safety data.
Option B: Option B is incorrect because withholding controller therapy in a woman with moderate persistent asthma at 28 weeks of gestation is clinically dangerous and contrary to all asthma management guidelines; uncontrolled asthma during pregnancy carries significant fetal risks including preterm birth, growth restriction, and perinatal mortality that are substantially greater than the risks of appropriately managed controller therapy.
Option C: Option C is incorrect because ICS systemic absorption does not increase as gestational lung volume decreases; low-dose ICS produces minimal systemic absorption regardless of gestational stage; fetal adrenal suppression from appropriately dosed ICS in the mother is not a recognized clinical concern at guideline-recommended doses; this option justifies montelukast preference on a pharmacological premise that does not reflect established clinical pharmacology.
Option E: Option E is incorrect because GINA guidelines do not recommend that non-steroidal controllers should always be trialed before ICS in pregnant patients; inhaled budesonide is specifically recommended as the preferred first-line choice for moderate persistent asthma in pregnancy, not a second-line fallback after LTRA failure; delaying effective ICS therapy in a 28-week pregnant patient with moderate persistent asthma for a four-week montelukast trial exposes both mother and fetus to the risks of inadequately controlled asthma.
9. A 42-year-old man with moderate persistent asthma and AERD (aspirin-exacerbated respiratory disease) was started on zileuton (Zyflo CR) three months ago as an add-on controller agent. He presents for his scheduled three-month liver function test (LFT) monitoring visit. He feels well, denies jaundice, right upper quadrant pain, or fatigue. Laboratory results show ALT (alanine aminotransferase) 168 U/L (upper limit of normal 42 U/L; 4× ULN [upper limit of normal]), AST (aspartate aminotransferase) 92 U/L (2.2× ULN), and bilirubin within normal limits. Which of the following most accurately identifies the required clinical action?
A) Continue zileuton at the current dose and repeat LFTs in one month; an ALT of 4× ULN without jaundice or symptoms represents a mild transaminase elevation that is clinically acceptable during zileuton therapy; the FDA prescribing information permits continued zileuton use until ALT exceeds 10× ULN or jaundice develops
B) Discontinue zileuton immediately; an ALT elevation exceeding 3× ULN during zileuton therapy meets the contraindication threshold specified in the FDA prescribing information, regardless of whether the patient is symptomatic; the drug should be stopped and LFTs monitored until they normalize, with an alternative controller agent selected for ongoing asthma and AERD management
C) Reduce the zileuton dose by 50% and repeat LFTs in two weeks; dose reduction is the appropriate response to moderate transaminase elevation during zileuton therapy, as hepatotoxicity is dose-dependent and sub-therapeutic doses maintain 5-LOX (5-lipoxygenase) inhibitory activity while reducing hepatic enzyme induction; full-dose therapy can be resumed once ALT falls below 2× ULN
D) Add ursodeoxycholic acid (UDCA) to the regimen to provide hepatoprotection while continuing zileuton; the transaminase elevation is expected in the first three to six months of zileuton therapy and represents an adaptive hepatic response rather than true drug-induced liver injury; UDCA will normalize LFTs within four to six weeks without requiring zileuton discontinuation
E) Withhold zileuton for two weeks and repeat LFTs; if ALT normalizes to below 1× ULN within two weeks of holding the drug, the elevation was zileuton-related and the drug can be cautiously restarted at the same dose with weekly LFT monitoring; zileuton-related transaminase elevations are universally reversible on rechallenge and recurrent elevation does not occur
ANSWER: B
Rationale:
This patient's ALT elevation of 4× ULN at the three-month monitoring visit meets the FDA-specified contraindication threshold for zileuton discontinuation. The zileuton prescribing information specifies that the drug is contraindicated in patients with active hepatic disease and in patients with liver enzyme elevations greater than three times the upper limit of normal — whether at baseline or developing during therapy. An ALT of 168 U/L in a patient whose ULN is 42 U/L represents a 4× ULN elevation, which exceeds this threshold. The absence of symptoms (jaundice, right upper quadrant pain, fatigue) and normal bilirubin are reassuring findings but do not alter the FDA-specified management threshold; the structured LFT monitoring protocol exists precisely to identify asymptomatic enzyme elevation before symptomatic hepatocellular injury develops. The required action is immediate zileuton discontinuation, with follow-up LFTs to confirm normalization. An alternative controller agent — such as montelukast or a return to ICS/LABA-based optimization — should be selected for ongoing AERD and asthma management.
Option A: Option A is incorrect because the FDA prescribing information does not permit continued zileuton use until 10× ULN or jaundice — this threshold is far above the 3× ULN contraindication level; continuing zileuton at 4× ULN elevation would risk progression to clinically significant hepatocellular injury; the monitoring protocol is designed to identify and act on enzyme elevations at the 3× ULN threshold.
Option C: Option C is incorrect because dose reduction is not an established or FDA-supported management strategy for zileuton-associated transaminase elevation exceeding 3× ULN; the prescribing information specifies discontinuation at this threshold, not dose adjustment; there is no evidence that reducing the dose maintains efficacy while resolving hepatotoxicity in this setting.
Option D: Option D is incorrect because zileuton-associated transaminase elevation exceeding 3× ULN is not an expected adaptive hepatic response that resolves without intervention; while mild transaminase elevations in the first months of therapy may occur and are monitored, an elevation of 4× ULN requires drug discontinuation; ursodeoxycholic acid is not an established hepatoprotective intervention for drug-induced liver injury from zileuton and does not substitute for drug discontinuation.
Option E: Option E is incorrect because the FDA prescribing information does not endorse a rechallenge protocol for zileuton in patients who have developed transaminase elevations exceeding 3× ULN; rechallenge after drug-induced hepatotoxicity carries risk of recurrent and potentially more severe injury; and the characterization that zileuton-related elevations are "universally reversible on rechallenge without recurrence" is not supported by the pharmacological evidence or prescribing guidelines.
10. A 78-year-old man with COPD (chronic obstructive pulmonary disease) on chronic theophylline therapy is brought to the emergency department after his wife found him unresponsive. His theophylline level is 44 mcg/mL. An ECG (electrocardiogram) shows sustained monomorphic ventricular tachycardia at 158 beats per minute with a blood pressure of 84/52 mmHg. He is intubated for airway protection. Activated charcoal has been administered via nasogastric tube. Despite IV (intravenous) amiodarone 300 mg, the ventricular tachycardia persists. Which of the following most accurately identifies the definitive next intervention and its pharmacological rationale?
A) Administer IV adenosine 6 mg as a rapid bolus; theophylline's mechanism of toxicity is adenosine A1 receptor antagonism, so exogenous adenosine at high IV doses will competitively overcome theophylline's receptor blockade, restore physiological A1-mediated SA (sinoatrial) node inhibition, and terminate the ventricular tachycardia through direct pharmacological reversal of the toxic mechanism
B) Administer IV phenytoin 20 mg/kg loading dose; phenytoin is the anticonvulsant and antiarrhythmic agent specifically effective against theophylline-induced cardiac toxicity because it acts on voltage-gated sodium channels that are uniquely sensitized by theophylline's adenosine receptor antagonism, providing both rhythm stabilization and seizure prophylaxis
C) Administer IV propranolol; beta-blockade will terminate the ventricular tachycardia by reducing catecholamine-driven cardiac stimulation and reversing theophylline-induced hypokalemia through beta-2 receptor blockade, restoring potassium from skeletal muscle back into the serum; however, propranolol should be used with caution given the underlying COPD and must be dose-titrated against bronchospasm monitoring
D) Perform synchronized direct current cardioversion at 200 joules to terminate the hemodynamically unstable ventricular tachycardia; after successful cardioversion, begin continuous IV magnesium sulfate infusion to stabilize the myocardial membrane and prevent VT (ventricular tachycardia) recurrence while oral activated charcoal and multi-dose charcoal eliminate residual theophylline
E) Initiate emergent hemodialysis; this patient's theophylline level of 44 mcg/mL combined with life-threatening hemodynamically unstable ventricular tachycardia that has failed antiarrhythmic therapy meets the established threshold for emergent themodialysis, which will rapidly remove theophylline from the circulation, reduce adenosine A1 receptor antagonism, and allow catecholamine-driven arrhythmia substrate to resolve as the theophylline concentration falls
ANSWER: E
Rationale:
This patient meets all criteria for emergent hemodialysis on multiple independent grounds: a theophylline level of 44 mcg/mL in the context of chronic toxicity (the hemodialysis threshold for chronic theophylline toxicity is approximately 40–60 mcg/mL, compared with greater than 90 mcg/mL for acute overdose), combined with a life-threatening hemodynamically unstable ventricular tachycardia that has already failed first-line antiarrhythmic therapy with amiodarone. The critical pharmacological principle is that theophylline-induced arrhythmias in severe toxicity are driven by two compounding mechanisms — adenosine A1 receptor antagonism at the SA (sinoatrial) and AV (atrioventricular) nodes, and catecholamine-driven cardiac stimulation with hypokalemia-lowered ventricular threshold — that cannot be reliably addressed by antiarrhythmic drugs when the theophylline concentration remains at 44 mcg/mL. Hemodialysis directly removes theophylline from the circulation (theophylline is approximately 40% protein-bound and has a relatively small volume of distribution, making it highly dialyzable); as the concentration falls, adenosine receptor occupancy by theophylline decreases, catecholamine release diminishes, and the arrhythmia substrate resolves at its pharmacological source. Multi-dose activated charcoal has already been initiated for ongoing GI elimination, which should be continued; but given the clinical severity, hemodialysis is the definitive intervention.
Option A: Option A is incorrect because administering IV adenosine to overcome theophylline's A1 receptor antagonism is not an established or safe clinical intervention; theophylline's non-competitive A1 receptor antagonism means that the concentration of exogenous adenosine required to compete effectively would produce marked bradycardia and AV block risk in a patient with theophylline-sensitized cardiac tissue; this approach is not supported by clinical evidence or guidelines.
Option B: Option B is incorrect because phenytoin is not specifically effective against theophylline-induced ventricular tachycardia; it acts through sodium channel blockade but is not established as the antiarrhythmic agent of choice for theophylline toxicity; the mechanism described — sodium channel sensitization by adenosine receptor antagonism — does not accurately reflect theophylline's cardiac toxicity mechanism.
Option C: Option C is incorrect because propranolol, while theoretically capable of reducing catecholamine-driven cardiac stimulation, is relatively contraindicated in a patient with known COPD requiring intubation; non-selective beta-blockade in a patient with obstructive lung disease risks severe bronchospasm; and while beta-2 blockade would redistribute potassium back into serum, this effect alone would not terminate life-threatening ventricular tachycardia at a theophylline level of 44 mcg/mL.
Option D: Option D is incorrect because synchronized DC cardioversion may temporarily terminate the VT but will not prevent rapid recurrence as long as the theophylline concentration remains at 44 mcg/mL; continuous IV magnesium sulfate does not address the underlying pharmacokinetic cause; the combination of cardioversion plus charcoal without addressing theophylline removal by dialysis leaves the patient at immediate risk for recurrent hemodynamically unstable VT.
11. A 49-year-old man with AERD (aspirin-exacerbated respiratory disease) and coronary artery disease underwent successful aspirin desensitization 14 months ago and has been maintained on aspirin 650 mg twice daily without any AERD reactions. He develops acute bacterial sinusitis and is seen by his otolaryngologist, who considers antibiotic options. The otolaryngologist is aware that some antibiotics require aspirin to be held due to bleeding risk augmentation and asks which prescribing consideration is most important in this patient. Which of the following most accurately identifies the key prescribing constraint and appropriate management strategy?
A) Any antibiotic that inhibits CYP2C9 (cytochrome P450 2C9) should be avoided in this patient because CYP2C9 is responsible for aspirin's metabolic inactivation; CYP2C9 inhibition would raise aspirin serum concentrations to supratherapeutic levels, increasing both AERD reaction risk and bleeding risk simultaneously; amoxicillin-clavulanate is preferred because it has no CYP2C9 interaction
B) Clindamycin should be avoided because it is metabolized by the same hepatic CYP1A2 pathway as theophylline and aspirin, creating competitive inhibition that dramatically raises aspirin plasma concentrations; azithromycin is the preferred antibiotic because it is excreted renally without hepatic CYP metabolism and therefore does not interact with aspirin's clearance pathway
C) Antibiotic selection must avoid any agent for which bleeding risk or drug interaction guidelines would prompt clinicians to hold the maintenance aspirin; if aspirin is held for more than one to two days, the desensitized state will reverse, and the patient's next aspirin dose will trigger a full AERD reaction; amoxicillin-clavulanate or a cephalosporin is the preferred choice for uncomplicated acute bacterial sinusitis in a penicillin-tolerant patient, as these agents carry no indication to hold aspirin and will allow maintenance therapy to continue uninterrupted
D) The primary prescribing concern is that most antibiotics used for sinusitis inhibit leukotriene biosynthesis through bacterial lipopolysaccharide suppression, temporarily reducing the constitutive cysteinyl leukotriene overproduction that characterizes AERD; this transient reduction in leukotriene synthesis can paradoxically destabilize the desensitized state by allowing CysLT1 (cysteinyl leukotriene receptor 1) receptor upregulation during reduced receptor occupancy; a macrolide antibiotic should be used because its additional anti-inflammatory properties will maintain CysLT1 receptor downregulation throughout the treatment course
E) Fluoroquinolone antibiotics are contraindicated in this patient because they inhibit CYP1A2 and substantially reduce aspirin clearance, raising aspirin plasma concentrations to levels that overwhelm the desensitized state's CysLT1 receptor downregulation and trigger a breakthrough AERD reaction at concentrations above 800 mg per dose; amoxicillin is preferred and the aspirin dose should be temporarily reduced to 325 mg twice daily during the fluoroquinolone course
ANSWER: C
Rationale:
The central prescribing constraint in this patient is maintaining uninterrupted aspirin continuity. The desensitized state achieved through aspirin desensitization is pharmacologically fragile: it depends entirely on continuous aspirin use, and the tolerant state reverses within days — sometimes as few as two to three days — of aspirin discontinuation, as CysLT1 receptor downregulation and EP2 (prostaglandin E2 receptor subtype 2) upregulation revert toward the patient's baseline AERD phenotype. Once reversed, the next aspirin dose is pharmacologically equivalent to an aspirin challenge in a naïve AERD patient, triggering the full COX-1 inhibition-driven cysteinyl leukotriene surge. The antibiotic selection therefore must avoid any agent for which the prescribing physician, surgeon, or anesthesiologist would be prompted to hold the maintenance aspirin — whether due to bleeding risk augmentation, drug interaction, or procedural protocol. For uncomplicated acute bacterial sinusitis in a penicillin-tolerant patient, amoxicillin-clavulanate or a first-to-second-generation cephalosporin (such as cefdinir) are appropriate first-line choices with no clinical indication to hold aspirin. These agents have no pharmacokinetic interaction with aspirin and no bleeding risk augmentation that would prompt aspirin discontinuation. This patient's concurrent coronary artery disease further underscores the importance of uninterrupted aspirin — both for cardiac protection and for AERD desensitization maintenance.
Option A: Option A is incorrect because aspirin is not primarily metabolized by CYP2C9; aspirin is rapidly hydrolyzed to salicylate by plasma and tissue esterases, not by CYP enzymes; CYP2C9 inhibition does not raise aspirin concentrations and the pharmacological mechanism described is inaccurate; amoxicillin-clavulanate is indeed a reasonable antibiotic choice, but for the correct reason (no aspirin-hold indication) rather than the incorrect CYP2C9 reasoning.
Option B: Option B is incorrect because clindamycin is not metabolized by CYP1A2 in competition with aspirin; aspirin itself is not metabolized by CYP1A2; azithromycin is metabolized by CYP3A4, not renally excreted as a primary route; the pharmacological mechanism described does not exist, and the antibiotic recommendation is based on a false premise.
Option D: Option D is incorrect because antibiotics used for sinusitis do not inhibit leukotriene biosynthesis through lipopolysaccharide suppression or any other recognized mechanism; this mechanism is pharmacologically invented; macrolide antibiotics have modest anti-inflammatory properties but do not maintain CysLT1 receptor downregulation through the mechanism described; and macrolides (particularly erythromycin and clarithromycin) inhibit CYP3A4 and would increase concentrations of any co-administered CYP3A4-metabolized drugs.
Option E: Option E is incorrect because fluoroquinolones reduce theophylline levels (not aspirin levels) through CYP1A2 inhibition; aspirin is not a CYP1A2 substrate; fluoroquinolones do not raise aspirin concentrations; and there is no indication to reduce the aspirin dose to 325 mg during a fluoroquinolone course — the entire premise of the interaction described is pharmacologically incorrect.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.